Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 286

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 286
---
 $300,000 per
year.

14

The global antiviral drugs market is experiencing
significant growth, driven by the increasing prevalence of viral infections and advancements in treatment options. In 2022, the market
was valued at approximately $49.8 billion and is projected to reach around $71.1 billion by 2032, reflecting a compound annual growth
rate (CAGR) of 3.73% during this period.

Specifically focusing on avian influenza (bird
flu), the treatment market was estimated at $22.06 billion in 2023 and is expected to grow at a CAGR of 8.18%, reaching approximately
$38.27 billion by 2030.

These figures highlight the substantial market opportunity for innovative
treatments addressing chronic, age-related, and viral diseases. With increasing demand for therapies targeting oxidative stress, cellular
degeneration, and immune resilience, Telomir-1 is well-positioned to address these critical unmet medical needs. Its broad therapeutic
potential, spanning rare diseases, metabolic disorders, neurodegeneration, and viral infections, represents a significant market opportunity
across North America and beyond, reinforcing its potential as a transformative solution in modern medicine.

Intellectual
Property

We
license the U.S. patent rights for the use of Telomir-1 in human applications from MIRALOGX, LLC (“MIRALOGX”), an intellectual
property development and holding company.  MIRALOGX has filed a Patent Cooperation Treaty (PCT) application, PCT/US2023/073106 on
August 29, 2023. The application designated the U.S. and will enter U.S. national phase. The application, if granted and subject to payment
of patent maintenance fees, would offer protection extending through at least August 29, 2043 in the U.S. The patent rights for Telomir-1
outside of the United States are not included in our current patent rights.

Our
license from MIRALOGX is set forth in an Amended and Restated Exclusive License Agreement, dated August 11, 2023, between us and MIRALOGX,
pursuant to which we obtained the exclusive perpetual right and license under the above-described patent rights to make, have made, use,
and sell “Licensed Products” in the U.S. for human uses and pre-clinical studies and activities of any kind conducted in
furtherance of